George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksByotrol Regulatory News (BYOT)

Share Price Information for Byotrol (BYOT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.15
Bid: 0.10
Ask: 0.20
Change: -0.225 (-60.00%)
Spread: 0.10 (100.00%)
Open: 0.275
High: 0.275
Low: 0.075
Prev. Close: 0.375
BYOT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

First US Retail Trial with Target

17 May 2018 07:00

RNS Number : 3364O
Byotrol PLC
17 May 2018
 

 

 

17th May, 2018

Byotrol plc

("Byotrol" or the "Company") 

 

FURTHER PROGRESS IN THE US

 

MASS MARKET RETAIL TRIAL WITH TARGET

 

 

Byotrol plc, the specialist anti-microbial technology company, is pleased to announce that it has secured its first mass market retail trial in the US, for its 24-hour germ-kill surface sanitizer 'Byotrol24'.

 

The trial is due to take place over approximately 10-12 weeks at the national retailer Target. We are expecting the trial to start next month in approximately 10% of Target's 1,829 stores, following which Target will decide whether it wishes to roll-out into nationwide distribution.

 

This progress follows on closely from the Company having completed individual US State product registration earlier this month. Byotrol24 received formal approval from the US Environmental Protection Agency in June 2017.

 

 

 

David Traynor, Chief Executive of Byotrol plc comments:

 

"This is really good news for Byotrol. Target Corporation is one of the leading general merchandise retailers in the US and is well-known for innovation and design; it is a perfect retail match for our brand and an excellent first step in pursuing our US commercialisation ambitions."

 

 

 

Enquiries:

David Traynor - Chief Executive, Byotrol plc 01925 742 000

David Paton - Investor Relations 07714 190 474

 

 

finnCap Ltd 020 7220 0500 (Nominated Adviser & Broker)

Geoff Nash/Kate Bannatyne - Corporate Finance

Richard Chambers - Corporate Broking

 

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

Notes to Editors:

 

Byotrol plc (BYOT.L), quoted on AIM, is a specialist developer of residual antimicrobial technologies, identifying, developing, formulating and commercialising cutting-edge antimicrobial solutions.

 

Our patented suite of technologies deliver powerful broad-spectrum efficacy with residual performance optimised against commonly occurring and industry-specific pathogens.

 

Founded in 2005, the Company has developed advanced antimicrobial technologies that create easier, safer and cleaner lives for everyone.

 

For more information, please go to www.byotrol.co.uk

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTLLFIRELIRLIT
Date   Source Headline
28th Mar 20247:00 amRNSProposed Cancellation
22nd Dec 202311:44 amRNSHolding(s) in Company
7th Dec 20237:00 amRNSHalf-year Report
14th Nov 20237:00 amRNSLaunch of PROCESSUS® Instrument Decontamination
14th Nov 20237:00 amRNSTrading Update
9th Nov 20233:43 pmRNSHolding(s) in Company
27th Sep 20237:00 amRNSBoard Changes
13th Sep 20233:33 pmRNSResult of AGM
8th Sep 20234:33 pmRNSDirector Dealing
7th Sep 20237:01 amRNSBoard Appointment
7th Sep 20237:00 amRNSTrading Update
29th Aug 20238:51 amRNSLaunch of CHEMGENE MEDLAB into human healthcare
23rd Aug 20237:00 amRNSInvestor Presentation via Investor Meet Company
31st Jul 20237:00 amRNSFinal Results
6th Jul 20237:00 amRNSPatent Grant for Novel Anti-viral Seaweed Extract
24th May 20233:14 pmRNSUS EPA approves Byotrol24 as long-lasting virucide
24th May 20238:51 amRNSDirector Dealing
28th Apr 20239:57 amRNSDirector Dealing
27th Apr 20237:00 amRNSTrading Update and Board Changes
1st Feb 20239:52 amRNSDirector Dealing
22nd Dec 20223:08 pmRNSDirector Dealing
19th Dec 202210:00 amRNSDirector Dealing
16th Dec 20227:00 amRNSGrant of Share Incentive Awards
12th Dec 20227:00 amRNSInterim results and Investor Presentation
22nd Nov 20227:00 amRNSDirectorate Changes
27th Sep 202211:15 amRNSPDMR Shareholding
22nd Sep 20225:21 pmRNSResult of AGM
8th Sep 20227:00 amRNSDirector Dealing
2nd Sep 202210:02 amRNSInvestor Presentation
30th Aug 20227:00 amRNSFinal Results
12th Aug 20223:30 pmRNSDirector Dealing
28th Jul 20227:00 amRNSCompletion of Convertible Loan Note Fundraising
11th Jul 20227:00 amRNSTrading Update and Notice of Results
22nd Apr 20229:14 amRNSHolding(s) in Company
2nd Mar 20227:00 amRNSTrading Update
12th Jan 20227:00 amRNSSenior Management Appointment
14th Dec 20219:06 amRNSSecond Price Monitoring Extn
14th Dec 20219:00 amRNSPrice Monitoring Extension
13th Dec 20217:00 amRNSDirectorate Change
9th Dec 20218:51 amRNSDirector Dealing
8th Dec 20217:00 amRNSInterim Results and Investor Presentation
2nd Nov 20217:00 amRNSDirectorate and Senior Management Changes
1st Nov 202111:36 amRNSTotal Voting Rights
1st Nov 202111:20 amRNSHolding(s) in Company
28th Oct 202111:40 amRNSExercise of Options & Total Voting Rights
20th Oct 20214:46 pmRNSResult of AGM
1st Oct 20217:00 amRNSSale of Byotrol24 in the Americas
27th Sep 20214:36 pmRNSPosting of Annual Report & Accounts/Notice of AGM
1st Sep 20217:00 amRNSInvestor Presentation
20th Aug 202110:01 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.